



# Biotech Daily

Tuesday May 27, 2025

*Daily news on ASX-listed biotechnology companies*

- \* **ASX, BIOTECH UP: 4D MEDICAL UP 15%; CURVEBEAM DOWN 10%**
- \* **LUMOS: 'CGS TAKES MEDICARE FEBRIDX TO 85% OF THE US'**
- \* **ATOMO: NAPWHA \$450k HIV SELF-TEST ORDER**
- \* **OPTISCAN DEVELOPS MICROSCOPE SOFTWARE PROTOTYPE**
- \* **PAINCHEK, ELDERMARK SELL PAIN SOFTWARE IN US**
- \* **PRESCIENT DOSES 1st PHASE IIa PTX-100 LYMPHOMA PATIENT**
- \* **IMUGENE 34-TO-1 SHARE CONSOLIDATION EGM**
- \* **NEUREN 98.5% BACK DIRECTOR FEE HIKE AGM**
- \* **AVECHO 97% SUPPORT 16m BOARD OPTIONS AGM**
- \* **MARK AZZI TAKES 8% OF NYRADA**

## MARKET REPORT

The Australian stock market was up 0.56 percent on Tuesday May 27, 2025, with the ASX200 up 46.6 points to 8,407.6 points.

Twenty of the Biotech Daily Top 40 companies were up, 13 fell and seven traded unchanged. All four Big Caps were up.

4D Medical was the best for the second day in a row, up 4.5 cents or 14.75 percent to 35 cents, with 2.6 million shares traded. Optiscan climbed 13.6 percent; Nova Eye was up 8.3 percent; Resonance rose 7.5 percent; Atomo was up 6.25 percent; Actinogen and Cynata were up five percent or more; Neuren and Prescient increased more than four percent; Aroa, Cyclopharm, Dimerix, Nanosonics and Resmed rose two percent or more; Botanix, Clinuvel, Cochlear, Immutep, Mesoblast, Pro Medicus, Proteomics, Syntara and Telix were up more than one percent; with CSL up by 0.8 percent.

Curvebeam led the falls, down 0.9 cents or 10 percent to 8.1 cents, with 639,494 shares traded. Impedimed lost 6.25 percent; Paradigm fell 4.7 percent; Compumedics, EBR and Genetic Signatures were down more than three percent; Amplia and Universal Biosensors shed two percent or more; Alcidion, Medadvisor and Polynovo were down more than one percent; with Avita and Orthocell down by less than one percent.

### LUMOS DIAGNOSTICS

Lumos says the Nashville, Tennessee, CGS Administrators has added Febridx to its Medicare Fee Schedule, at \$US41.38 (\$A63.80) per test, retroactively from May 1, 2025. In 2023, Lumos said it had US Food and Drug Administration clearance to market and sell its Febridx point-of-care, finger-prick blood test to differentiate bacterial from viral respiratory infections (BD: Jul 11, 2022; Jul 3, 2023).

Last year, the company said the US Centers for Medicare and Medicaid Services would reimburse Febridx at \$US41.38 a test (BD: Dec 5, 2024).

In April and May, Lumos said its test was added to the Medicare Schedule at Novitas, Palmetto, First Coast Service Options, Noridian Healthcare and Wisconsin Physicians Service (WPS), with more than 70 percent US coverage (BD: Apr 17, 23, May 19, 2025). Today, the company said that CGS was responsible for managing Medicare payments in Kentucky and Ohio; and with the addition of CGS, the test was reimbursed by six of seven US Medicare administrative contractors, covering more than 85 percent of the US.

Lumos said that National Government Services (NGS), responsible for the US states of Illinois, Wisconsin and Minnesota, was the last remaining contractor to cover Febridx.

Lumos managing-director Doug Ward said “securing additional Medicare coverage from CGS for Febridx reinforces our commitment to developing a point-of-care diagnostic solution that not only benefits patients but also integrates seamlessly into care pathways and delivers value to the broader health system”.

“Lumos remains committed to securing adoption from the remaining [Medicare administrative contractor], NGS, and pursuing reimbursement coverage from private payors, with the goal of achieving nationwide access for patients and supporting broad clinical adoption of Febridx,” Mr Ward said.

Lumos was unchanged at 2.7 cents.

### ATOMO DIAGNOSTICS

Atomo says the Federal Government-funded National Association of People with HIV Australia (NAPHWA) has ordered \$450,000 of its HIV finger-prick self-tests.

Last year, Atomo said it had an order for \$440,000 of its HIV blood tests from NAPHWA, as part of an “ongoing scale-up of a successful free-to-user HIV self-testing program run by NAPHWA” (BD: Nov 13, 2024).

Today, the company said following last year’s Federal Budget, NAPHWA had “proven successful in increasing testing rates among key high-risk cohorts who had not been testing sufficiently or, in many cases, not testing at all”.

Last year, Atomo said it supplied the only approved HIV self-test in Australia and that the Budget provided \$43.9 million in funding for HIV prevention, testing, workforce training and information, and the Federal Government was committed to “eliminating HIV transmission by 2030” (BD: May 15, 16, 2024).

Today, the company said the program was supported by Grindr, “the world’s largest social networking [application] for the LGBTQI+ community, and expansion of the program ensures availability of more HIV self-tests” and allowed Grindr to build awareness and provide users with links to access self-testing resources in Australia.

Atomo managing-director John Kelly said the company was “very pleased with the positive response from the community to the at-home program and we will continue to work with NAPHWA and other partners here in Australia to ensure that discrete, convenient testing is available to those wishing to know their status”.

Atomo was up 0.1 cents or 6.25 percent to 1.7 cents.

## OPTISCAN

Optiscan says it has developed a prototype of its internet “cloud-based tele-pathology streaming software” for use with its medical devices and microscopes.

In 2023, Optiscan said that with the Mississauga, Ontario-based software developer Prolucid Technologies it would develop artificial intelligence (A.I.) algorithms and tele-pathology workflows for its confocal laser endo-microscopes (BD: Jan 30, 2023).

Today, the company said the platform allowed for the live streaming of microscopic imaging sessions, with pathologists and clinicians able to remotely access and interpret high-resolution images as they were generated, allowing pathologists and clinicians to review sessions, annotate images, generate reports and work with clinicians on-line. The company said it had completed the minimum viable product stage of development and would continue to focus on validating the platform in “real-world settings, incorporating user feedback, and preparing for broader clinical deployment”.

Optiscan managing-director Prof Camile Farah said the collaboration allowed the company “to develop a seamless and secure workflow that bridges the gap between onsite real-time microscopic imaging and real-time remote pathology interpretation”.

“This platform is a potential game changer for global digital pathology, with particular relevance to regional, rural, and remote healthcare settings where access to pathology expertise is limited,” Prof Farah said. “By removing these barriers, we’re bringing high-quality digital pathology to anyone, anywhere, anytime.”

“Our telepathology solution essentially brings the pathologist into the heart of the operating theatre and bridges the gap between surgery and pathology,” Prof Farah said. Optiscan was up 1.5 cents or 13.6 percent to 12.5 cents.

## PAINCHEK

Painchek says the Minneapolis, Minnesota-based Eldermark Software LLC will sell its pain assessment and monitoring application in the US, effective immediately.

Painchek said Eldermark had been a provider of “dedicated senior living solutions in the US and Canada for 30 years, with more than 116,000 client users” and the non-exclusive deal would integrate its artificial intelligence (A.I.) and facial recognition-based pain assessment tool with Eldermark’s care management system.

The company said sales would begin following US Food and Drug Administration clearance of its adult smartphone application, targeting the US “long-term care market”.

The company said the financial impact could not be quantified as it was a reseller agreement “based on Eldermark’s best efforts to promote Painchek’s technology”.

Painchek was up 0.4 cents or 8.3 percent to 5.2 cents with 5.6 million shares traded.

## PRESCIENT THERAPEUTICS

Prescient says it has dosed the first of up-to 40 patients in its phase IIa trial of PTX-100 for relapsed and refractory cutaneous T-cell lymphoma, a type of blood cancer.

Last year, Prescient said it had US Food and Drug Administration investigational new drug approval for a phase II trial of PTX-100 for T-cell lymphoma (BD: Jan 19, 2025).

In March, the company said the study would be held in Australia, the US and Europe and evaluate two doses of PTX-100 (BD: Mar 26, 2025).

Today, Prescient chief medical officer Dr Marissa Lim said the first patient was “dosed at the Linear Clinical Research site in Perth, under the care of Dr Dejan Radeski, a consultant haematologist with a special interest in T-cell lymphoma”.

Prescient was up 0.2 cents or 4.2 percent to five cents with 1.4 million shares traded.

## IMUGENE

Imugene says its extraordinary general meeting will vote to approve a 34-to-one share consolidation, as well as the issue of shares under its placement.

Earlier this month, Imugene said it would seek shareholder approval for a 34-to-one share consolidation and that if approved its about 7,467,020,803 shares on issue would become 219,618,259 shares on issue post-consolidation (BD: May 16, 2025).

At that time, the company said the consolidation was expected to increase the market price per share "to reflect the reduced number of shares on issue".

Today, Imugene said, subject to shareholder approval, the consolidation would be effective from June 30, 2025.

The meeting will be held online and at McCullough Robertson, Level 32, 25 Martin Place, Sydney on June 26, 2025 at 9am (AEST).

Imugene was unchanged at 1.7 cents with 30.0 million shares traded.

## NEUREN PHARMACEUTICALS

Neuren says its annual general meeting has overwhelmingly approved all four resolutions, including 98.47 percent in favor of an increase to its director fee pool.

Last month, Neuren said shareholders would vote to increase its aggregate non-executive director fee pool by 50 percent from \$500,000 to \$750,000 following "an external benchmarking process" (BD: Apr 24, 2025).

Today, the company said the remaining resolutions including the re-election of directors Dianne Angus and Jenny Harry as well as the approval of auditor fees and expenses were supported by more than 98.74 percent of the meeting.

Neuren was up 60 cents or 4.5 percent to \$14.05 with 724,540 shares traded.

## AVECHO BIOTECHNOLOGY

Avecho says its annual general meeting has overwhelmingly passed all resolutions with more than 96.79 percent in support of 15,846,489 options to its board.

Last month, Avecho said the meeting would vote to issue 6,338,595 options to chair Dr Greg Collier and 3,169,298 options to directors Dr Ross Murdoch, Matt McNamara and Kathy Connell, each (BD: Apr 24, 2025).

Today, the company said shareholders approved the remuneration report, the re-election of Dr Collier as a director and its 10 percent placement facility.

Avecho was unchanged at 0.5 cents with 7.3 million shares traded.

## NYRADA

Nyrada says Mark Azzi has increased his substantial shareholding in Nyrada from 13,301,800 Chess depositary interests (CDIs) (6.31%) to 17,389,920 CDIs (8.25%).

Nyrada was up half a cent or 3.6 percent to 14.5 cents.